Brazilian Court Invalidates Gilead’s Patent For Hepatitis C Drug.

Reuters (9/24, Marcello, Slattery) reports a court in Brazil stripped Gilead Sciences of the exclusivity of its patent for a “big-selling hepatitis C treatment,” invalidating the company’s rights to the drug Sovaldi (sofosbuvir). One of the candidates fo...